<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03433703</url>
  </required_header>
  <id_info>
    <org_study_id>E7080-M001-222</org_study_id>
    <nct_id>NCT03433703</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)</brief_title>
  <official_title>A Single-Arm, Multicenter, Phase 2 Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the safety and tolerability of subsequent
      treatment of physician's choice (TPC) following the first-line lenvatinib treatment in
      unresectable hepatocellular carcinoma (uHCC) participants.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Treatment-emergent Adverse Events</measure>
    <time_frame>Up to 30 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Treatment-emergent Serious Adverse Events</measure>
    <time_frame>Up to 30 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>OS will be measured from the date of the first dose of study treatment until the date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>PFS is defined as the time from the date of the first dose of first-line lenvatinib treatment to the date of the first documentation of disease progression, or the date of death during the subsequent treatment of physician choice (TPC), whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>TTP is defined as the time from the date of the first dose of first-line lenvatinib treatment to the date of the first documentation of disease progression during subsequent TPC.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <arm_group>
    <arm_group_label>Lenvatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive lenvatinib 12 or 8 milligrams (mg) once daily in continuous 28-day cycles until disease progression, development of unacceptable toxicity, participant request, withdrawal of consent, or study termination by the sponsor. Upon completion of lenvatinib treatment, participants may continue to receive commercially available treatment for hepatocellular carcinoma in the subsequent treatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>Lenvatinib capsules will be administered orally, once daily in continuous 28-day cycles.
Body weight (BW) ≥60 kilograms (kg) - Lenvatinib 12 mg (taken as three 4-mg capsules); BW &lt;60 kg - Lenvatinib 8 mg (taken as two 4-mg capsules)</description>
    <arm_group_label>Lenvatinib</arm_group_label>
    <other_name>LENVIMA®</other_name>
    <other_name>E7080</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Participants must have confirmed diagnosis of unresectable Hepatocellular Carcinoma
             (uHCC) with any of the following criteria:

               1. Histologically or cytologically confirmed diagnosis of HCC

               2. Clinically confirmed diagnosis of HCC according to American Association for the
                  Study of Liver Diseases criteria, including cirrhosis of any etiology or with
                  chronic hepatitis B or C infection criteria

          -  At least one measurable target lesion regardless if hepatic or non-hepatic according
             to modified Response Evaluation Criteria in Solid Tumors (mRECIST) meeting the
             following criteria:

               1. Hepatic lesion

                    -  The lesion can be accurately measured in at least one dimension as ≥1.0
                       centimeters (cm) (viable tumor for typical; and longest diameter for
                       atypical), and

                    -  The lesion is suitable for repeat measurement,

               2. Nonhepatic lesion

                    -  Lymph node lesion that measures at least one dimension as ≥1.5 cm in the
                       short axis

                    -  Non-nodal lesion that measures ≥1.0 cm in the longest diameter Lesions
                       previously treated with radiotherapy or locoregional therapy must show
                       radiographic evidence of disease progression to be deemed a target lesion.

          -  Participants categorized on the Barcelona Clinic Liver Cancer staging system to Stage
             B (not applicable for transarterial chemoembolization) or Stage C

          -  Adequate bone marrow function, liver function, blood coagulation function, renal
             function, and pancreatic function as assessed by laboratory tests.

          -  Adequately controlled blood pressure (BP) with up to 3 antihypertensive agents,
             defined as BP ≤150/90 millimeters of mercury (mmHg) at Screening and no change in
             antihypertensive therapy within 1 week prior to Cycle 1/Day 1

          -  Child-Pugh A

          -  Eastern Cooperative Oncology Group Performance Status of 0 or 1

          -  Survival expectation of 12 weeks or longer before starting study drug

        Key Exclusion Criteria:

          -  Imaging findings for HCC corresponding to any of the following:

               1. HCC with ≥50% liver occupation

               2. Clear invasion into the bile duct

               3. Portal vein invasion at the main portal branch (Vp4)

          -  Participants who have received any systemic chemotherapy, including sorafenib,
             regorafenib or other anti-vascular endothelial growth factor therapy, nivolumab, or
             any systemic investigational anticancer agents, including lenvatinib, for
             advanced/uHCC.

          -  Participants who have received any anticancer therapy (including surgery, percutaneous
             ethanol injection, radio frequency ablation, transarterial [chemo] embolization,
             hepatic intra-arterial chemotherapy, biological, immunotherapy, hormonal, or
             radiotherapy) or any blood enhancing treatment (including blood transfusion, blood
             products, or agents that stimulate blood cell production, e.g., granulocyte
             colony-stimulating factor) within 28 days prior to the first dose of lenvatinib study
             treatment.

          -  Participants who have not recovered from toxicities as a result of prior anticancer
             therapy such as the local hepatic injection chemotherapy or any prior therapy for
             other cancer types.

          -  Significant cardiovascular impairment within 6 months of the first dose of study drug

          -  Prolongation of QT interval corrected for heart rate using Fridericia's correction
             (QTcF) to &gt;480 milliseconds (ms)

          -  Gastrointestinal malabsorption or any other condition that might affect the absorption
             of lenvatinib in the opinion of the investigator

          -  Bleeding or thrombotic disorders or use of anticoagulants such as warfarin or similar
             agents requiring therapeutic international normalized ratio monitoring

          -  Gastrointestinal bleeding event or active hemoptysis (bright red blood of at least
             half teaspoon) within 28 days prior to the first dose of lenvatinib study treatment

          -  Gastric or esophageal varices that require treatment

          -  Active malignancy (except for HCC or definitively treated melanoma in-situ, basal or
             squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix) within the
             past 36 months

          -  Any history of or current brain or subdural metastases

          -  Participants having &gt;1+ proteinuria on urine dipstick testing will undergo 24-hour
             urine collection for quantitative assessment of proteinuria. Participants with urine
             protein ≥1 grams/24 hour will be ineligible

          -  Arterial-portal venous shunt or arterial-venous shunt preventing proper diagnosis of
             tumor

          -  Any medical or other condition that in the opinion of the investigator would preclude
             the participant's participation in a clinical study

          -  Known intolerance to lenvatinib or any of the excipients

          -  Human immunodeficiency virus positive or active infection requiring treatment (except
             for hepatitis virus)

          -  Any history of drug or alcohol dependency or abuse within the prior 2 years

          -  Major surgery within 3 weeks prior to the first dose of lenvatinib study treatment or
             scheduled for surgery during the study

          -  Participant has had a liver transplant

          -  Females who are breastfeeding or pregnant at Screening or Baseline

          -  Females of childbearing potential who within 28 days before study entry did not use a
             highly effective method of contraception or do not agree to use a highly effective
             method of contraception throughout the entire study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eisai Medical Information, EJ</last_name>
    <phone>1-888-274-2378</phone>
    <email>esi_medinfo@eisai.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>California Liver Research Institute</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mena Edward, MD</last_name>
      <phone>626-440-7325</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2018</study_first_submitted>
  <study_first_submitted_qc>February 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2018</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Unresectable hepatocellular carcinoma</keyword>
  <keyword>Lenvatinib</keyword>
  <keyword>E7080</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

